The GLP-compliant study serves as a critical IND-enabling milestone for the company’s regenerative technology. By utilizing patient-derived cells combined with proprietary biomaterials, Matricelf aims to create autologous implants tailored to individual physiological needs. The absence of abnormal findings across all study endpoints provides the clinical data necessary to advance the company’s regulatory roadmap.

CEO Gil Hakim noted that the successful completion of this safety program validates the core technology. While the company still faces ongoing preclinical benchmarks and financing requirements, the latest data marks a shift from laboratory research toward potential human application. Matricelf remains focused on securing the necessary authorizations to move these engineered implants into hospital settings for patients suffering from paralysis.